EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Vor Biopharma's Enterprise Value is $18.20 Mil.
Vor Biopharma's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2023 was $-101.36 Mil. Therefore, Vor Biopharma's EV-to-FCF for today is -0.18.
The historical rank and industry rank for Vor Biopharma's EV-to-FCF or its related term are showing as below:
VOR'
s EV-to-FCF Range Over the Past 10 Years
Min: -1.72 Med: 0 Max: 0.43
Current: -0.18
During the past 6 years, the highest EV-to-FCF of Vor Biopharma was 0.43. The lowest was -1.72. And the median was 0.00.
VOR's EV-to-FCF is ranked worse than 100% of 393
companies
in the Biotechnology industry
Industry Median: 4.52
vs VOR: -0.18
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
The historical data trend for Vor Biopharma's EV-to-FCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Vor Biopharma's EV-to-FCF
For the Biotechnology subindustry, Vor Biopharma's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Vor Biopharma's EV-to-FCF Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Vor Biopharma's EV-to-FCF distribution charts can be found below:
* The bar in red indicates where Vor Biopharma's EV-to-FCF falls into.
Vor Biopharma EV-to-FCF Calculation
Vor Biopharma's EV-to-FCF for today is calculated as:
Vor Biopharma's current Enterprise Value is $18.20 Mil.
Vor Biopharma's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-101.36 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Vor Biopharma (NAS:VOR) EV-to-FCF Explanation
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
Vor Biopharma's PE Ratio for today is calculated as:
Vor Biopharma's share price for today is $1.80.
Vor Biopharma's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-1.750.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.
Vor Biopharma EV-to-FCF Related Terms
Thank you for viewing the detailed overview of Vor Biopharma's EV-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.
Vor Biopharma (Vor Biopharma) Business Description
Vor Biopharma Inc is a clinical stage cell therapy company. It combines a novel patient engineering approach with targeted therapies to provide a solution for patients suffering from hematological malignancies. The company's products include VOR33.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
VOR has been successfully added to your 